Adam Friedman, MD, FAAD defines non-medical therapeutic switching and discusses common tactics payors use to pressure practitioners and patients to switch.
Expert Perspectives on the Clinical Impact of Non-Medical Therapeutic Switching
An expert in dermatology discusses the potential impact of non-medical switching to biosimilars and generic formulations on safety and efficacy profiles.
Adam Friedman, MD, FAAD provides insight into how non-medical therapeutic switching affects clinical, economic, and psychological outcomes for patients.
A key opinion leader emphasizes the importance of discouraging non-medical switching by communicating with patients and partnering with industry researchers.
Adam Friedman, MD, FAAD discusses how payors accelerated non-medical switching during COVID-19 and how healthcare providers can respond to new challenges.
Advertisement
Advertisement
Trending on HCPLive
1
The HCPFive: Top News for Healthcare Providers from the Week of 06/21
2
Expanding Use of Dupilumab in Pediatric Patients, With Ilona Frieden, MD
3
When the Allergen Is Not What You Expected: 2 Contact Dermatitis Cases
4
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
5